Skip to main content
Journal cover image

Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system.

Publication ,  Journal Article
Webb, KS; Poulton, SH; Liberman, SN; Walther, PJ
Published in: J Urol
August 1989

A family of triple hybridomas secreting hybrid monoclonal antibodies has been developed in our laboratory. The hybrid monoclonal antibodies exhibit bimolecular specificity towards both antigenic determinants on the prostate carcinoma cell surface as well as toxin or toxic moieties (ricin A chain and pokeweed antiviral protein). These hybrid antibodies, when bound univalently to their cognate toxin, constitute the primary reagents responsible for selective in vitro prostate carcinoma cell kill; oncolytic impact is achieved by binding of the hybrid antibody-toxin complex (primary hybrid immunotoxin) to a prostate carcinoma cell surface-expressed antigen by the remaining univalent binding site of the hybrid antibody, allowing access of the toxin to the cytosol by internalization of the hybrid antibody-toxin complex. Internalization by endocytosis of a hybrid antibody-toxic subunit has been strikingly enhanced by the use of secondary monoclonal antibody reagents alone or in conjunction with other biomodifier reagents. For example, use of a second monoclonal antibody specific for ricin A chain to which ricin B chain (binding subunit) is chemically coupled results in selective and synergistic cell kill of targeted cancer cells. In vitro studies involving temporally staggered exposure of the cells to the individual components (primary hybrid antibody, toxin, and secondary antitoxin monoclonal antibody biomodifier) have been performed in a manner allowing maintenance of cytotoxic efficacy. It is concluded that sequential administration of these immunotherapeutic components, individually nontoxic, is a feasible strategy to develop an effective immunotherapeutic treatment of human prostate carcinoma.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Urol

DOI

ISSN

0022-5347

Publication Date

August 1989

Volume

142

Issue

2 Pt 1

Start / End Page

425 / 432

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Tumor Cells, Cultured
  • Ricin
  • Ribosome Inactivating Proteins, Type 1
  • Prostatic Neoplasms
  • Plant Proteins
  • Neoplasm Transplantation
  • N-Glycosyl Hydrolases
  • Mice, Nude
  • Mice
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Webb, K. S., Poulton, S. H., Liberman, S. N., & Walther, P. J. (1989). Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system. J Urol, 142(2 Pt 1), 425–432. https://doi.org/10.1016/s0022-5347(17)38778-5
Webb, K. S., S. H. Poulton, S. N. Liberman, and P. J. Walther. “Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system.J Urol 142, no. 2 Pt 1 (August 1989): 425–32. https://doi.org/10.1016/s0022-5347(17)38778-5.
Webb KS, Poulton SH, Liberman SN, Walther PJ. Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system. J Urol. 1989 Aug;142(2 Pt 1):425–32.
Webb, K. S., et al. “Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system.J Urol, vol. 142, no. 2 Pt 1, Aug. 1989, pp. 425–32. Pubmed, doi:10.1016/s0022-5347(17)38778-5.
Webb KS, Poulton SH, Liberman SN, Walther PJ. Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system. J Urol. 1989 Aug;142(2 Pt 1):425–432.
Journal cover image

Published In

J Urol

DOI

ISSN

0022-5347

Publication Date

August 1989

Volume

142

Issue

2 Pt 1

Start / End Page

425 / 432

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Tumor Cells, Cultured
  • Ricin
  • Ribosome Inactivating Proteins, Type 1
  • Prostatic Neoplasms
  • Plant Proteins
  • Neoplasm Transplantation
  • N-Glycosyl Hydrolases
  • Mice, Nude
  • Mice